Xingmeng Biopharmaceutical

Xingmeng Biopharmaceutical is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, specializing in the development of innovative biologics and high-end biosimilars. The company focuses on therapeutic areas with high clinical demand, including allergy, infectious diseases, and ophthalmology. Its lead asset, SYN008, is a biosimilar of the blockbuster drug Xolair (omalizumab) and is currently undergoing Phase 3 clinical trials for the treatment of asthma and chronic urticaria. Xingmeng also advances SYN004, a human monoclonal antibody designed for rabies post-exposure prophylaxis, which aims to provide a safer and more effective alternative to traditional rabies immunoglobulins. With a fully integrated platform spanning R&D to GMP manufacturing, the company is positioned to deliver affordable, high-quality biological therapies to the global market.